Cargando…

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy

Detalles Bibliográficos
Autores principales:	Schwab, Katjana S., Kristiansen, Glen, Isaak, Alexander, Held, Stefanie E. A., Heine, Annekristin, Brossart, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530425/ https://www.ncbi.nlm.nih.gov/pubmed/31157170 http://dx.doi.org/10.3389/fonc.2019.00403

Ejemplares similares

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia
por: Schwab, K.S., et al.
Publicado: (2016)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Ipilimumab/nivolumab/tozinameran: Various toxicities: case report
Publicado: (2022)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
por: Jiang, Huihui, et al.
Publicado: (2021)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
por: Vos, Joris L., et al.
Publicado: (2021)

Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
por: Johnson, Jennifer M, et al.
Publicado: (2023)

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
por: Glutsch, Valerie, et al.
Publicado: (2019)

Correction to: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
por: Jiang, Huihui, et al.
Publicado: (2021)

Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer
por: Koshizuka, Keiichi, et al.
Publicado: (2020)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
por: Brastianos, Priscilla K., et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial
por: Harrington, Kevin J., et al.
Publicado: (2023)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
por: Lai, Gillianne G.Y., et al.
Publicado: (2022)

Diffuse alveolar hemorrhage with nivolumab monotherapy
por: Shannon, Vickie R., et al.
Publicado: (2020)

Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma
por: Sadagopan, Narayanan, et al.
Publicado: (2019)

Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma
por: Moein, Hamid-Reza, et al.
Publicado: (2021)

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
por: Danno, Tetsuya, et al.
Publicado: (2021)

Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment
por: Takayama, Koichiro, et al.
Publicado: (2022)

Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer
por: Derks, Sarah, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
por: Yang, Yi, et al.
Publicado: (2020)

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis
por: Serritella, Anthony V., et al.
Publicado: (2023)

Complete Remission of Colon Cancer with Ipilimumab Monotherapy
por: Suzuki, Sho, et al.
Publicado: (2020)

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
por: Suozzi, Kathleen C., et al.
Publicado: (2016)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bhbk5e5vgv7jocuos664m54698